🔴 AIM is trading 6.4% down today on mixed reaction to clinical and investor updates

AIM is trading at $0.34 (6.4% down) today following mixed market reactions to recent clinical and corporate developments.

• The company announced the completion of enrollment for its DURIPANC trial, with clinical data results expected in 2027.
• AIM is scheduled to present at the Webull Corporate Connect Webinar Series on June 24–25, 2026, which may be prompting repositioning by speculative biotech investors.